Fritextsökning
Artiklar per år
Innehållstyper
-
Tio life science-projekt får miljonanslag – ny utlysning öppnar
En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.
-
Life science trends 2025 – Part 1 obesity drugs
More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obesity has a different mechanism of action, writes Samuel Lagercrantz in the first article in a series of trend insights for 2025. Today: obesity.
-
FDA approves new cystic fibrosis therapy
A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).
-
New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"
For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require immunosuppressive drugs. "A major immunological breakthrough," says Professor Per-Ola Carlsson, who leads the clinical study, to Life Science Sweden.
-
Rise and Scantox cease conducting animal testing in Stockholm
Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs are high, and demand is weak”, says the division manager at Rise to Life Science Sweden.
-
Novo Nordisk establishes new factory in Denmark
Novo Nordisk establishes a new production facility in Odense, Denmark, an investment of 8.5 billion Danish kroner.
-
Hypothesis testing versus conspiracy theory
"How do you know what is a conspiracy theory and what is a reasonable, scientifically based conclusion?" In a column, Ingrid Lönnstedt reflects on this question.
-
Partial court victory for entrepreneur who lost his company
Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in connection with losing his company, Tataa Biocenter.
-
MSD discontinues development of cancer drugs after trial failures
MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.
-
Norwegian cancer research companies merge
The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.
-
Joy at Egetis after positive CHMP opinion – ”The single most important milestone”
Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."
-
Lösning hittad för Orexos patenttvist
En långdragen patenttvist mellan Uppsalabolaget Orexo och indiska Sun Pharmaceutical Industries är nu löst genom förlikning.
-
Lilly recruits top Swedish researcher in Alzheimer´s
One of Sweden's leading Alzheimer's researchers, Oskar Hansson, has been recruited by pharma giant Eli Lilly and will be moving to the USA.
-
600 million SEK for life science - "Should not be the country of moderation"
Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.
-
Bredd och spets på välbesökt life science-event
Hela kedjan inom läkemedelsframställning – från den tidiga forskningen till fyllning av vialer – var representerad när konferensen New Horizons in Biologics & Bioprocessing ägde rum på torsdagen.
-
Starka resultat för genterapi – pausas ändå
En ny genterapi förbättrade synen hos elva av tolv patienter med en extremt sällsynt ärftlig ögonsjukdom. Men trots de starka resultaten i en klinisk studie har den fortsatta utvecklingen lagts i malpåse. ”Det är väldigt frustrerande för patienterna”, säger Anders Kvanta, professor och överläkare vid S:t Eriks ögonsjukhus.
-
Large study on milk: Risky for women but not for men
The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while no such association was found in men, according to a new large Swedish study.
-
Thomas Eldered: ”Innovation is the key”
Thomas Eldered speaks in a web clip about the challenges facing the life science sector in the future and what he, as an investor, finds most interesting in new companies.
-
“Research is always a lot of failures and a few successes”
Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessible to more people. “Our overall ambition is to reduce costs a hundredfold”, says professor Johan Rockberg at KTH Royal Institute of Technology in Stockholm.
-
Jättestudie om mjölk: Riskfyllt för kvinnor men inte för män
Risken för hjärtinfarkt ökade för kvinnor som i genomsnitt drack minst två glas mjölk om dagen, medan det hos män inte återfanns något sådant samband i en ny stor svensk studie.
-
”Forskning är alltid en massa misslyckanden och några få succéer”
Genterapier öppnar fantastiska möjligheter, men är också extremt dyra att producera. Genenova ska ändra på det – och göra läkemedlen tillgängliga för fler. ”Vår övergripande ambition är att minska kostnaderna hundrafalt”, säger KTH-professorn Johan Rockberg.
-
Anna Törner: ”If I fall seriously ill, I’ll move to Finland”
”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.
-
Amerikansk vård-vd sköts till döds på öppen gata
Vd:n för det amerikanska hälsovårdsbolaget United Healthcare, Brian Thompson, sköts ihjäl på Manhattan i New York på onsdagsmorgonen.
-
Novo Nordisk to invest billions in new quality control lab
Novo Nordisk has announced plans to invest 2.9 billion Danish kroner in order to establish a new quality control laboratory in Hillerød in northern Zealand, Denmark.